BMI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Badger Meter is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 available. The stock has had a sharp fundamental and price reset after weak Q1 2026 results, and while the business may improve later in the year, the current setup is still uneven. At 127.28, the shares are trading near resistance and the recent analyst tone is mixed-to-negative. If the investor is impatient and unwilling to wait for a cleaner entry, this is not the best immediate buy.
BMI is in a short-term recovery attempt but not yet in a strong uptrend. MACD histogram is positive at 2.019, which is constructive, but it is positively contracting, suggesting momentum is losing strength. RSI_6 is 61.2, showing neutral-to-mildly bullish conditions rather than an oversold rebound. Moving averages are converging, which usually signals indecision. Price is sitting just below/around resistance at R1 127.376, very close to the current price of 127.28, while support sits at 121.52 and then 115.664. The stock trend model points to weak near-term returns, with downside expected over the next week and month, so the technical setup does not support an aggressive long-term entry today.
["Some analysts still maintain bullish ratings and see second-half acceleration potential after the Q1 air pocket.", "Baird and RBC both kept positive ratings while trimming targets, implying longer-term confidence remains.", "Management and analysts suggest the Q1 weakness may be timing-related rather than structural.", "Post-market move was positive at 2.04%, showing some dip-buying interest."]
["Q1 2026 sales declined 9% year over year and the stock fell 24% after the report.", "Guidance and analyst commentary point to a first-half air pocket and reliance on a second-half rebound.", "Maxim downgraded the stock to Hold and cut EPS estimates materially.", "Barclays has an Underweight rating and says the stock still screens expensive versus muted growth.", "News also includes a securities fraud investigation related to product demand and growth statements.", "Recent historical news shows prior major earnings-related drops, reinforcing fragile sentiment."]
Latest quarter: Q1 2026. The company reported a 9% year-over-year sales decline, which triggered a sharp selloff. Analyst commentary indicates softer short-cycle order rates and project timing issues, with expectations for a second-half rebound. For a long-term investor, the key issue is that growth has clearly slowed in the most recent quarter, and near-term visibility remains weak even if the longer-term franchise is still intact.
Analyst sentiment has deteriorated recently. Maxim downgraded BMI to Hold and cut EPS estimates sharply. RBC kept Outperform but reduced its target to 169 from 197. Baird also cut its target but stayed positive at Outperform. Barclays is the most bearish with an Underweight and a 110 target. JPMorgan remains Overweight but lowered its target to 160 after the Q1 miss. Overall Wall Street is split: bulls argue the Q1 weakness is temporary and that the second half should recover, while bears argue valuation is still too rich for the slower growth profile.
